Private Advisor Group LLC Buys Shares of 12,904 Hims & Hers Health, Inc. (NYSE:HIMS)

Private Advisor Group LLC purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 12,904 shares of the company’s stock, valued at approximately $312,000.

Other institutional investors also recently made changes to their positions in the company. Principal Financial Group Inc. lifted its stake in Hims & Hers Health by 370.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock valued at $33,024,000 after purchasing an additional 1,075,355 shares during the last quarter. Wellington Management Group LLP lifted its stake in Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares during the last quarter. Geode Capital Management LLC lifted its stake in Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares during the last quarter. Rhumbline Advisers lifted its stake in Hims & Hers Health by 93.8% during the fourth quarter. Rhumbline Advisers now owns 516,224 shares of the company’s stock valued at $12,482,000 after purchasing an additional 249,854 shares during the last quarter. Finally, Blueshift Asset Management LLC raised its holdings in shares of Hims & Hers Health by 834.8% during the third quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company’s stock valued at $4,513,000 after acquiring an additional 218,804 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HIMS. Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Leerink Partners upped their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Finally, TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $37.23.

Hims & Hers Health Trading Up 1.2 %

NYSE HIMS opened at $40.96 on Thursday. The company has a fifty day simple moving average of $37.34 and a 200 day simple moving average of $27.27. The company has a market cap of $9.10 billion, a P/E ratio of 93.08 and a beta of 1.35. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 78,127 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74. Following the completion of the sale, the chief executive officer now directly owns 109,956 shares of the company’s stock, valued at $3,256,896.72. This represents a 41.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Chi sold 7,259 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $32.25, for a total transaction of $234,102.75. Following the completion of the transaction, the insider now owns 184,947 shares of the company’s stock, valued at approximately $5,964,540.75. This represents a 3.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,062,011 shares of company stock valued at $36,892,724 in the last ninety days. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.